Trilostane monitoring in canine hyperadrenocorticism: can basal cortisol measurement replace the ACTH stimulation test?

Published:

2021-09-01

Share
Open Access Logo

DOI

https://doi.org/10.18849/ve.v6i3.412

Abstract

PICO question

In dogs with hyperadrenocorticism that are being treated with trilostane, does the measurement of basal cortisol levels have comparable diagnostic performance to the adrenocorticotropic hormone (ACTH) stimulation test?

 

Clinical bottom line

Category of research question

Diagnosis (effectiveness of treatment monitoring)

The number and type of study designs reviewed

Four cross-sectional diagnostic accuracy studies were critically reviewed

Strength of evidence

Weak to moderate (level 2)

Outcomes reported

There is evidence of moderate strength suggesting that basal cortisol measured at 4–6 hours (and possibly 2–3 hours) post-trilostane can be a good test to exclude adrenal oversuppression, while its use is not suggested for diagnostic confirmation of oversuppression. There is evidence of weak strength that basal cortisol might be helpful for identifying dogs with inadequate adrenal suppression, but cannot be used to rule it out

Conclusion

Although the evaluation of the available evidence is difficult due to its heterogeneity, there is moderate evidence that a basal cortisol measured at 4–6 hours (and possibly 2–3 hours) post-trilostane dose can be a good test to rule out adrenal oversuppression, but that it cannot be used to definitively diagnose oversuppression. The current evidence suggests that basal cortisol is less useful for identification of inadequate control. Based on one included study, neither ACTH-stimulated nor basal cortisol levels correlate optimally with the actual clinical response of the patient. In this context, it can be concluded that none of the currently used laboratory tests should be used as a sole monitoring tool in dogs with hyperadrenocorticism receiving trilostane and thus, the assessment of the clinical response is of utmost importance

 

How to apply this evidence in practice

The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.

Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.

References

Alenza, D.P., Arenas, C., Lopez, M.L. & Melian, C. (2006). Long-Term Efficacy of Trilostane Administered Twice Daily in Dogs With Pituitary-Dependent Hyperadrenocorticism. Journal of the American Animal Hospital Association. 42(4), 269–276. DOI: http://dx.doi.org/10.5326/0420269

Arenas Bermejo, C.A., Alenza, D.P., San José, P.G., Llauet, L., Pérez‐López, L., Melián, C. & Feldman, E.C. (2020). Laboratory assessment of trilostane treatment in dogs with pituitary‐dependent hyperadrenocorticism. Journal of Veterinary Internal Medicine.34(4), 1413–1422. DOI: https://doi.org/10.1111/jvim.15830

Balshem, H., Helfand, M., Schunemann, H.J., Oxman, A.D., Kunz, R., Brozek, J., Vist, G.E., Falck‐Ytter, Y., Meerpohl, J., Norris, S. & Guyatt, G.H. (2011). GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology. 64(4), 401–406. DOI: https://doi.org/10.1016/j.jclinepi.2010.07.015

Behrend, E. (2015). Canine hyperadrenocorticism. In: E. Feldman, R. Nelson, C. Reusch & J. Scott-Moncrieff, ed., Canine and Feline Endocrinology, 4th St Louis: Elsevier, 377–451.

Bonadio, C.M., Feldman, E.C., Cohen, T.A. & Kass, P.H. (2014). Comparison of Adrenocorticotropic Hormone Stimulation Test Results Started 2 versus 4 Hours after Trilostane Administration in Dogs with Naturally Occurring Hyperadrenocorticism. Journal of Veterinary Internal Medicine. 28(4), 1239–1243. DOI: http://dx.doi.org/10.1111/jvim.12357

Boretti, F.S., Holzthuem, J., Reusch, C.E. & Sieber-Ruckstuhl, N.S. (2016). Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment. Schweizer Archiv für Tierheilkunde. 158(9), 631–638. DOI: http://dx.doi.org/10.17236/sat00083

Burkhardt, W.A., Boretti, F.S., Reusch, C.E. & Sieber‐Ruckstuhl, N.S. (2013). Evaluation of Baseline Cortisol, Endogenous ACTH, and Cortisol/ACTH Ratio to Monitor Trilostane Treatment in Dogs with Pituitary‐Dependent Hypercortisolism. Journal of Veterinary Internal Medicine. 27(4), 919–923. DOI: http://dx.doi.org/10.1111/jvim.12111

Cook, A.K. & Bond, K.G. (2010). Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism. Journal of the American Veterinary Medical Association. 237(7), 801–805. DOI: http://dx.doi.org/10.2460/javma.237.7.801

Lemetayer, J. & Blois, S. (2018). Update on the use of trilostane in dogs. The Canadian Veterinary Journal. 59(4), 397–407. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855282/ [Accessed 20/04/2021]

Macfarlane, L., Parkin, T. & Ramsey, I. (2016). Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs. Veterinary Record. 179(23), 597. DOI: http://dx.doi.org/10.1136/vr.103744

Ramsey, I.K. (2010). Trilostane in dogs. Veterinary Clinics of North America: Small Animal. 40(2), 269–83. DOI: http://dx.doi.org/10.1016/j.cvsm.2009.10.008

Wehner, A., Gloeckner, S., Sauter-Louis, C., Kruse, D., Stockhaus, C. & Hartmann, K. (2013). Association between ACTH stimulation test, clinical signs, and laboratory parameters in dogs with hyperadrenocorticism treated with trilostane. Journal of Veterinary Internal Medicine. 28, DOI: http://dx.doi.org/10.1111/jvim.12278

Whiting, P.F., Rutjes, A.W., Westwood, M.E., Mallett, S., Deeks, J.J., Reitsma, J.B., Leeflang, M.M.G., Sterne, J.A.C., Bossuyt, P.M. & the QUADAS-2 Group. (2011). QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Annals of Internal Medicine. 155, 529–536. DOI: http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00009

Woolcock, A.D., Bugbee, A.C. & Creevy, K.E. (2016). Evaluation of baseline cortisol concentration to monitor efficacy of twice-daily administration of trilostane to dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008–2012). Journal of the American Veterinary Medical Association. 248(7), 814–821. DOI: http://dx.doi.org/10.2460/javma.248.7.814

Vol. 6 No. 3 (2021): The third issue of 2021

Section: Knowledge Summaries

Categories :  Small Animal  /  Dogs  /  Cats  /  Rabbits  /  Production Animal  /  Cattle  /  Sheep  /  Pig  /  Equine  / 

Themes by Openjournaltheme.com